IRS Prioritizes §280E Tax Guidance Amidst Cannabis Rescheduling

The U.S. Treasury Department and Internal Revenue Service (IRS) have officially placed guidance concerning Section 280E of the tax code on their 2026-2027 Priority Guidance Plan. This move signals a significant focus on addressing the tax implications for cannabis businesses, particularly in light of recent federal rescheduling developments. The plan, which covers the period from October 1, 2026, to September 30, 2027, indicates that the IRS will dedicate efforts to clarifying how Section 280E applies to the evolving cannabis industry. While this designation highlights the issue, it does not set a firm deadline for the release of specific guidance.

Understanding Section 280E and Its Impact

Section 280E of the U.S. tax code generally prohibits businesses involved in trafficking Schedule I or Schedule II controlled substances from claiming ordinary business deductions and credits. For years, this has significantly impacted cannabis businesses, limiting their ability to reduce their taxable income. The federal rescheduling of certain cannabis products, particularly those used for medical purposes, has raised questions about whether these businesses will still be subject to the strict limitations of Section 280E. The IRS’s inclusion of this guidance on their priority list suggests they are preparing to provide clarity on this complex issue.

The Role of Federal Rescheduling

The Treasury and the IRS previously announced in April 2026 their intention to issue tax guidance tied to the federal rescheduling of cannabis. This action was influenced by a Department of Justice final rule that affected certain marijuana products and state medical marijuana activities. The agencies indicated that rescheduling would generally remove Section 280E as a barrier to deductions and credits for businesses no longer dealing in Schedule I or II substances. However, the specifics of how this applies, especially for businesses with mixed operations, remain unclear and are what the new guidance aims to address.

Challenges for Mixed-Operation Cannabis Businesses

Cannabis companies that operate in both medical and adult-use markets face unique challenges under the current tax framework. The potential relief from Section 280E for medical cannabis activities does not automatically extend to adult-use sales, which may still be subject to the code. This distinction necessitates clear guidance on how businesses should apportion shared expenses between different lines of business. Furthermore, companies are awaiting clarity on the timing of any tax relief, including whether it will apply retroactively or require specific actions to be claimed.

What the Priority Designation Means for Businesses

The inclusion of Section 280E guidance on the IRS’s priority list is a positive step for the cannabis industry, indicating that the agencies are actively working on the issue. However, it is important for businesses to understand that this designation is not final guidance. It does not change current tax treatment or guarantee immediate relief. Businesses should continue to consult with tax professionals to navigate their specific tax situations based on existing regulations and to prepare for future guidance that will likely clarify the tax treatment of their operations. The IRS aims to increase voluntary compliance by clarifying these ambiguous areas of tax law.

Frequently Asked Questions